37 results about "Leukemia lymphoma" patented technology

The invention belongs to the technical field of antibody medicines and provides two types of antibody compositions including CD45 antibody, CD13 antibody, CD33 antibody and CD7 antibody or including CD45 antibody, CD117 antibody, CD34 antibody and CD19 antibody. The invention further provides a leukemia and lymphoma typing kit comprising the two types of antibody compositions and capable of being used with a flow cytometry to achieve typing of various hematological neoplasms.

The present invention provides a method of combination therapy comprising administration of a tissue-targeting radio-pharmaceutical and a DNA-repair inhibitor. The method may be used in the treatment of hyperplastic or neoplastic disease, such as a carcinoma, sarcoma, myeloma, leukemia, lymphoma or mixed type cancer.

A pharmaceutical composition containing an anti-proliferative compound, named Tecomaphorbide, which is identified and isolated from Tecoma plants (e.g. Tecoma stans). The pharmaceutical composition may contain a derivative and/or a salt of Tecomaphorbide. A process of obtaining Tecomaphorbide from Tecoma plants is specified. A method of treating cancer (e.g. leukemia, lymphoma, breast, colon, and prostate cancer) with the pharmaceutical composition is also provided.

The invention discloses an application of 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1H-indole-3-yl) ethanone or pharmaceutically acceptable salt thereof in preparation ofa medicine for treating or preventing tumor diseases. The product is used for relieving and/or adjunctively treating and/or treating myeloma, leukemia, lymphoma, pancreatic cancer, gastric cancer, breast cancer, ovarian cancer, lung cancer, liver cancer, skin cancer, rectal cancer, prostate cancer, thyroid cancer and other tumors. The 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1 hydrogen-indole-3-yl) ethanone has a remarkable specific inhibition effect on PI3K gamma (polyisocyanurate).

The invention belongs to the technical field of pharmacy, and relates to an application of small molecule compounds ZINC5921027 and ZINC1413516 in preparation of human La protein inhibitors, in particular to an application in preparation of drugs for preventing, delaying or treating high-expression human La protein participated or mediated diseases. The small molecule compound can be effectively combined with human La protein, inhibits the most basic biological function of the La protein, and plays a role of a human La protein inhibitor. The prepared human La protein inhibitor is suitable for treating malignant tumors participated or mediated by a high La protein expression pathway and diseases secondary to increase of virus replication participated or mediated by the high La protein expression pathway. The malignant tumors comprise ovarian cancer, cervical cancer, endometrial cancer, breast cancer, liver cancer, head and neck lymphocyte cancer, oral lymphocyte cancer, leukemia, lymphoma and the like. Diseases secondary to the increased virus replication include hepatitis B, hepatitis C and herpes simplex.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4)are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cellsurfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

The invention discloses an automatic cerebrospinal fluid cell analysis system based on artificial intelligence. The system comprises an establishment method of a cerebrospinal fluid cell image featurelibrary, a cerebrospinal fluid cell image feature acquisition method and device, and an automatic cerebrospinal fluid cell image identification and counting method. The invention overcomes the defects in the prior art, and provides a cerebrospinal fluid cell image library establishment method, a cerebrospinal fluid cell image acquisition method and device, and a cerebrospinal fluid cell image automatic identification and counting method. Feature extraction is automatically carried out on a cerebrospinal fluid cell image, pixel-level segmentation is carried out on cerebrospinal fluid cells, the segmented cerebrospinal fluid cells are classified, and cells of the whole cerebrospinal fluid cell image are counted. According to the invention, the working efficiency of brain cell detection is greatly improved, the labor intensity of workers is reduced, and an important cerebrospinal fluid cell detection means is provided for the diagnosis of diseases such as central nervous system infection, meningeal leukemia, lymphoma, cerebral parasitic diseases, cerebrovascular diseases, immune degeneration and the like.

De-ethylflavopereirine, a pharmaceutically acceptable salt thereof, a solvate or a hydrate thereof, or a pharmaceutically acceptable salt of a solvate or a hydrate thereof may be used as cancer therapy (i.e., prevention and/or treatment) in a subject in need thereof, including a pathological condition such as inflammation, especially chronic, or cancer (e.g., a carcinoma, a sarcoma, a melanoma, a leukemia, a lymphoma), especially a solid tumor and/or a metastasis thereof. In particular, systemic administration of such improved anti-cancer agents in effective amounts may selectively destroy cancer cells (including cancer stem cells) in a solid tumor and/or at a site of metastasis. They are well-tolerated by the subject, even at large systemic doses and their resulting high concentrations in the circulation, and provide safe and effective anti-cancer agents.

This invention relates to a human-derived bradeion protein having the following properties:

• [0001]
  • (i) it is a transmembranous protein;
  [0002]
  • (ii) it has a transmembranous portion, an extracellular portion, and a cytoplasmic portion in its molecule as determined by a hydrophobicity analysis according to Kyte-Doolittle method;
  [0003]
  • (iii) it is expressed in the human adult normal brain and heart, the expression level thereof in the heart being about 10% or lower of that in the brain, while it is not expressed in other adult normal organs of spleen, lung, liver, skeletal muscle, kidney and pancreas, and in fetal brain, lung, heart and kidney;
  [0004]
  • (iv) it induces programmed cell death when over-expressed in a cultured human brain-derived undifferentiated nerve cell line;
  [0005]
  • (v) it induces termination of cell division and aging when over-expressed in a cultured human brain-derived differentiated nerve cell;
  [0006]
  • (vi) it is located in cytoplasm in the course of the induced cell death, and forms an intracellular aggregate when overexpressed; and
  [0007]
  • (vii) it is expressed in a human colorectal cancer cell line or in a human malignant melanoma cell line, but not in leukemia, lymphoma and lung carcinoma,

to a DNA encoding said bradeion protein, to a vector comprising said DNA, to a host cell comprising said vector, and to a method for detecting a cancer such as colorectal cancer or malignant melanoma.

The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia/lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.